8-K 1 r8k-081.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 30, 2004 Access Pharmaceuticals, Inc. ------------------------------------------------------ (Exact name of registrant as specified in its charter) Delaware 0-9314 83-0221517 ------------------------ ------------------------ ------------------- (State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207 ----------------------------------------------- --------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (214) 905-5100 -------------- Item 8.01 Other Events ------------ On October 1, 2004, Access Pharmaceuticals, Inc. announced that the results from the Phase I clinical trial of AP5346 a DACH Platinum Polymer Therapeutic were presented on Friday, October 1, 2004 at the 16th EORTC-NCI-AACR Symposium in Geneva, Switzerland as a poster presentation. A copy of the press release regarding this announcement is attached as Exhibit 99.1 and is incorporated into this current report by reference. Item 9.01 Financial Statements Information and Exhibits. ---------------------------------------------- (c) Exhibits -------- 99.1 Press Release of Access Pharmaceuticals, Inc. dated October 1, 2004. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Access Pharmaceuticals, Inc. (Registrant) By: /s/ Stephen B. Thompson ------------------ Stephen B. Thompson Vice President and Chief Financial Officer Dated October 1, 2004 3 EXHIBIT INDEX Exhibit Number Description ------- ------------ 99.1 Press Release of Access Pharmaceuticals, Inc. dated October 1, 2004 4